Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 133

1.

Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease.

Kreuser ED, Felsenberg D, Behles C, Seibt-Jung H, Mielcarek M, Diehl V, Dahmen E, Thiel E.

Ann Oncol. 1992 Sep;3 Suppl 4:105-10.

PMID:
1280463
[PubMed - indexed for MEDLINE]
2.

Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.

Sieniawski M, Reineke T, Josting A, Nogova L, Behringer K, Halbsguth T, Fuchs M, Diehl V, Engert A.

Ann Oncol. 2008 Oct;19(10):1795-801. doi: 10.1093/annonc/mdn376. Epub 2008 Jun 9.

PMID:
18544558
[PubMed - indexed for MEDLINE]
Free Article
3.

Gonadal function following ABVD therapy for Hodgkin's disease.

Kulkarni SS, Sastry PS, Saikia TK, Parikh PM, Gopal R, Advani SH.

Am J Clin Oncol. 1997 Aug;20(4):354-7.

PMID:
9256888
[PubMed - indexed for MEDLINE]
4.

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M.

J Clin Oncol. 1998 Dec;16(12):3810-21.

PMID:
9850026
[PubMed - indexed for MEDLINE]
Free Article
5.

Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma.

Bokemeyer C, Schmoll HJ, van Rhee J, Kuczyk M, Schuppert F, Poliwoda H.

Ann Hematol. 1994 Mar;68(3):105-10.

PMID:
8167175
[PubMed - indexed for MEDLINE]
6.

Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease.

Kreuser ED, Xiros N, Hetzel WD, Heimpel H.

J Cancer Res Clin Oncol. 1987;113(3):260-6.

PMID:
3108263
[PubMed - indexed for MEDLINE]
8.

Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.

Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Loeffler M, Engert A, Josting A, Wolf J, Hasenclever D, Franklin J, Duehmke E, Georgii A, Schalk KP, Kirchner H, Doelken G, Munker R, Koch P, Herrmann R, Greil R, Anselmo AP, Diehl V.

J Clin Oncol. 2002 Jan 15;20(2):476-84.

PMID:
11786577
[PubMed - indexed for MEDLINE]
Free Article
9.

Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group.

Diehl V, Pfreundschuh M, Löffler M, Rühl U, Hiller E, Gerhartz H, Wilmanns W, Kirchner H, Schoppe W, Petsch S, et al.

Med Oncol Tumor Pharmacother. 1989;6(2):155-62.

PMID:
2473363
[PubMed - indexed for MEDLINE]
10.

Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid regimen.

Clark ST, Radford JA, Crowther D, Swindell R, Shalet SM.

J Clin Oncol. 1995 Jan;13(1):134-9.

PMID:
7799013
[PubMed - indexed for MEDLINE]
Free Article
11.

Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD.

Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G.

Eur J Cancer Clin Oncol. 1985 May;21(5):601-5.

PMID:
2408897
[PubMed - indexed for MEDLINE]
12.

Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.

Villani F, Busia A, Villani M, Laffranchi A, Viviani S, Bonfante V.

Anticancer Res. 2009 Feb;29(2):777-83.

PMID:
19331235
[PubMed - indexed for MEDLINE]
Free Article
13.

Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.

Brosteanu O, Hasenclever D, Loeffler M, Diehl V; German Hodgkin's Lymphoma Study Group.

Ann Hematol. 2004 Mar;83(3):176-82. Epub 2003 Dec 12.

PMID:
15064867
[PubMed - indexed for MEDLINE]
14.

The effects of etoposide on testicular function in boys treated for Hodgkin's disease.

Gerres L, Brämswig JH, Schlegel W, Jürgens H, Schellong G.

Cancer. 1998 Nov 15;83(10):2217-22.

PMID:
9827728
[PubMed - indexed for MEDLINE]
15.

Gonadal function in young patients successfully treated for Hodgkin disease.

Papadakis V, Vlachopapadopoulou E, Van Syckle K, Ganshaw L, Kalmanti M, Tan C, Sklar C.

Med Pediatr Oncol. 1999 May;32(5):366-72.

PMID:
10219339
[PubMed - indexed for MEDLINE]
16.

Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy.

Castelo-Branco C, Nomdedeu B, Camus A, Mercadal S, Martínez de Osaba MJ, Balasch J.

Fertil Steril. 2007 Mar;87(3):702-5. Epub 2006 Dec 13.

PMID:
17173900
[PubMed - indexed for MEDLINE]
17.

Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.

Tesch H, Diehl V, Lathan B, Hasenclever D, Sieber M, Rüffer U, Engert A, Franklin J, Pfreundschuh M, Schalk KP, Schwieder G, Wulf G, Dölken G, Worst P, Koch P, Schmitz N, Bruntsch U, Tirier C, Müller U, Loeffler M.

Blood. 1998 Dec 15;92(12):4560-7.

PMID:
9845521
[PubMed - indexed for MEDLINE]
Free Article
18.

Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease.

Salvagno L, Sorarù M, Sotti G, Aversa S, Chiarion Sileni V, Mazzarotto R, Scarzello G, Bianco A, Pappagallo GL, Fiorentino MV.

Ann Oncol. 1995 Feb;6(2):173-9.

PMID:
7540419
[PubMed - indexed for MEDLINE]
19.

Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group.

Takenaka T, Mikuni C, Miura A, Sasaki T, Suzuki H, Hotta T, Hirano M, Fukuhara S, Sugiyama H, Nasu K, Dohi H, Kozuru M, Tomonaga M, Tajima K, Niimi M, Fukuda H, Mukai K, Shimoyama M.

Jpn J Clin Oncol. 2000 Mar;30(3):146-52.

PMID:
10798542
[PubMed - indexed for MEDLINE]
Free Article
20.

Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin disease.

van den Berg H, Furstner F, van den Bos C, Behrendt H.

Pediatr Blood Cancer. 2004 Mar;42(3):210-5.

PMID:
14752856
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk